Platelets are small anucleate cells that circulate in the blood playing a central role in haemostasis, helping to heal any vascular damage by forming a vascular plug. Pathologically, platelet activation underlies thrombotic and heart disease, now recognised as the biggest killer of mankind in the western world.
The Platelet Proteomics group, led by Prof. Ángel García, is also part of the Instituto de Investigación Sanitaria de Santiago (IDIS) [Santiago Health Research Institute]. In our group, we are currently using a combination of proteomics technology and classical biochemistry to unravel the signal transduction events following the activation of the most relevant platelet receptors. We are focusing our studies on healthy and diseased platelets in order to identify novel biomarkers and drug targets that may help to treat / diagnose those diseases where unwanted platelet activation plays a role, such as acute coronary syndromes. In addition, we are currently searching for small molecule inhibitors of some of the most interesting targets identified by proteomics. We are also studying extracellular vesicles as a source of biomarkers in platelet-related diseases.
Divulgative video: http://tv.usc.es/mmobj/index/id/2862
For more information on the group, please visit the website: http://www.usc.es/biofarma/WebAngel/home.htm
Our research focus on the study of platelets and extracellular vesicles in those pathologies where an unwanted platelet activation plays a role, such as obesity and coronary artery disease. This is done by a combination of proteomic and functional approaches. The aim is to investigate platelets at molecular level to identify novel biomarkers and drug targets that may help to treat/diagnose atherothrombosis. Potential drug targets identified by proteomics are being investigated since a pharmacological point of view to find small molecules that can inhibit/modulate them.
Platelet Lipidome Fingerprint: New Assistance to Characterize Platelet Dysfunction in Obesity
Katacine is a new ligand of CLEC-2 that acts as a platelet agonist.
The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
Phosphoproteomic Analysis of Platelets in Severe Obesity Uncovers Platelet Reactivity and Signaling Pathways Alterations.
Deciphering the secretome of leukocyte-platelet rich fibrin: towards a better understanding of its wound healing properties.
A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade
Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients.